Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.

Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 06; 118(14):3922-31.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.